Biography

Dr Martin was born in Avila, Spain. Obtained the medical Degree at Zaragoza´s University and completed the Residence National Program at Clinic Hospital (Barcelona-Spain) in 2002. He has perfomed fellowship training at the UPMC Presbyterian Hospital in Pittsburgh, (PA-USA) and degree with Europpean Board. Also has completed a Degree in Health management and Hospitals Dr Martin has 20 years experience in Nuclear Medicine, with particularly interested in theragnosis, the combination of medical imaging diagnosis with radiation therapy. He is Chief of Nuclear Medicine at Cuenca´s General Hospital from 2004 and becomes in 2008 head of PET-CT and nuclear diagnostics for Alliance Medical-Spain. He resides close in Cuenca, with his wife, and enjoys life with his two sons and one grandchild. Combination of travelling, nature and lecture fulfil free time for Dr Martin.

---

Research Interest

*"Application of scintigraphy with 99mTc-immunoglobulin G human Polyclonal as prognostic factor in patients with rheumatoid arthritis". Clinical trial 97/529. * "Scan with tetrofosmin-99mTc for prediction of response to chemotherapy in lung cancer".Award end of residence Hospital Clínic 1999. * Palliative treatment with radiopharmaceuticals bone pain of metastatic (strontium-89 and samarium-153). *Lymphoscintigraphy for the detection of Sentinel lymph node in different types of tumors (melanoma, breast cancer), and carcinoma of vulva and penis *SPECT cerebral perfusion studies of epilepsy, both extratemporal temporal origin. *SPECT cerebral perfusion in patients with bipolar disorder. *Positron Emission Tomography (PET), clinical application and study of the fusion of image and co-registration PET/CT techniques. Presbyterian Hospital of the University of Pittsburgh. Pittsburgh, Pennsylvania. USA. *Applications of tomography positron emission (PET-CT) in tumors of head and neck. *Radioimmunotherapy with labeled antibodies (Rituximab-Zevalin) in lymphomas. *Brain perfusion SPECT in with schizophrenic disorders. *Technical assessment of the usefulness of tomography positron emission (PET-CT) in prostate Carcinoma. *Determination of the relative risk of pulmonary thromboembolism (TEP).